Form 4: Gilead CCO Johanna Mercier Reports Stock Transactions

Gilead Sciences' Chief Commercial Officer, Johanna Mercier, reported the acquisition of common stock through RSU conversion and subsequent sale of shares for tax obligations.

Summary

• Johanna Mercier, Chief Commercial Officer of Gilead Sciences, Inc., reported transactions involving the company's common stock and restricted stock units (RSUs).
• On December 10, 2025, 3,842 restricted stock units (RSUs) were converted into 3,842 shares of Gilead Sciences, Inc. common stock.
• Concurrently, 1,814 shares of common stock were disposed of at a price of $121.34 per share, likely to cover tax withholding obligations related to the RSU vesting.
• Following these transactions, Johanna Mercier directly beneficially owns 109,221 shares of common stock.
• Additionally, 27,674 restricted stock units remain beneficially owned directly.

Sentiment

Score: 5

Explanation: The filing reports a routine insider transaction related to equity compensation vesting and tax withholding, which is neutral in terms of company performance or significant new information.

Positives

• The conversion of 3,842 restricted stock units into common stock represents the vesting of previously granted equity compensation, indicating a successful milestone for the employee.

Negatives

• A disposition of 1,814 shares of common stock occurred, reducing the direct beneficial ownership of the reporting person, although this is a common practice for tax withholding upon RSU vesting.

Future Outlook

The filing indicates that the remaining restricted stock units have a four-year vesting schedule, with 25% vesting on the first anniversary of the grant date and the balance vesting 6.25% quarterly thereafter until fully vested.

Industry Context

This is a routine insider transaction related to equity compensation vesting, common across all industries for publicly traded companies, particularly in the biotechnology and pharmaceutical sectors like Gilead Sciences, Inc.

Stakeholder Impact

• Shareholders: The transaction is a routine insider filing and does not indicate any material change in company operations or strategy. The sale of shares for tax purposes is a common occurrence and generally not viewed as a negative signal.
• Employees (specifically Johanna Mercier): The vesting of RSUs represents a realization of compensation, aligning executive interests with shareholder value over the long term.

Next Steps

• Continued vesting of the remaining 27,674 restricted stock units according to the established four-year schedule.

Key Dates

Keywords

Gilead Sciences, GILD, Johanna Mercier, Chief Commercial Officer, Form 4, Insider Transaction, Restricted Stock Units, RSU, Common Stock, Equity Compensation, Stock Sale